Case Studies, Pharmaceutical

Case Study – Unidose Nasal Spray Pump in Hypoglycemia

The conventional rescue medicine for hypoglycemia is an intramuscular injection of glucagon which must be reconstituted at point of use. This case study describes a collaborative drug repurposing project with Aptar Pharma culminating in the development of a glucagon nasal powder, an easier to administer alternative. The product utilizes Aptar Pharma’s patented Unidose Powder (UDS) System, is easy-to-store, and has a shelf-life of two years from manufacture. It provides diabetes patients with a highly effective rescue medicine that can be administered by a range of potential carers. Success rates with the nasal powder have been shown to exceed those with injectable glucagon and the product’s market value is expected to exceed $150 million by 2025.

Download Case Study - Unidose Nasal Spray pump in hypoglycemia
8 Sep 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

3 Apr 2024

Delivering Nasally Administered Biologics

Webinars, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Market Insights

Read More
3 Apr 2024

Nasal Casts, Tools to Enable Nasal Drug Delivery Development

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
13 Mar 2024

In Silico Modelling for Orally Inhaled Drug Development (OINDP)

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 2 3 25

Request Access

Close

Requesting access to Case Study – Unidose Nasal Spray Pump in Hypoglycemia.

  • This field is for validation purposes and should be left unchanged.
Back To Top